Evidence map›Paper›PMID 35795812›Full record

ArticleArXiv2022

Modeling in higher dimensions to improve diagnostic testing accuracy: theory and examples for multiplex saliva-based SARS-CoV-2 antibody assays.

Rayanne A Luke, Anthony J Kearsley, Nora Pisanic, Yukari C Manabe, David L Thomas, Christopher D Heaney, Paul N Patrone

Open access · goldAbstract readPreprint
In one paragraph

Article in ArXiv, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rayanne A LukeJohns Hopkins University, Whiting School of Engineering, Department of Applied Mathematics and Statistics, Baltimore, MD.
Anthony J KearsleyNational Institute of Standards and Technology, Applied and Computational Mathematics Division, Gaithersburg, MD.
Nora PisanicJohns Hopkins University, Bloomberg School of Public Health, Department of Environmental Health and Engineering, Baltimore, MD.
Yukari C ManabeJohns Hopkins University, School of Medicine, Department of Medicine, Baltimore, MD.
David L ThomasJohns Hopkins University, School of Medicine, Department of Medicine, Baltimore, MD.
Christopher D HeaneyJohns Hopkins University, Bloomberg School of Public Health, Department of Environmental Health and Engineering, Baltimore, MD.
Paul N PatroneNational Institute of Standards and Technology, Applied and Computational Mathematics Division, Gaithersburg, MD.
Johns Hopkins University · USNational Institute of Standards and Technology · US

Funding

ECHODAC (Environmental Influences on Child Health Outcomes Data Analysis Center)U24OD023382 · OD · JOHNS HOPKINS UNIVERSITY · PI Diane J Catellier, LISA P JACOBSON · 2016 to 2026
$148.4M
TrainingU54EB007958 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Matthew Hamill · 2007 to 2026
$34.6M
Human Genetic determinants of HBV recoveryR01AI148049 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DUGGAL, PRIYA, THOMAS, DAVID L · 2020 to 2025
$4.7M
Antimicrobial resistant E. coli before and after California Senate bill 27 (ARES): a natural experimentR01AI130066 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI TARTOF, SARA · 2017 to 2021
$3.8M
Arsenic and immune response to influenza vaccination in pregnant women and newbornsR01ES026973 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI HEANEY, CHRISTOPHER D, LABRIQUE, ALAIN BERNARD · 2017 to 2021
$3.6M
Supplement to U01CA260469U01CA260469 · NCI · MICHIGAN STATE UNIVERSITY · PI LUCAS, TODD WILLIAM · 2020 to 2024
$3.2M
Multiplex oral fluid antibody assay for arbovirus diagnosis, surveillance and preventionR21AI139784 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COLLINS, MATTHEW, HEANEY, CHRISTOPHER D · 2018 to 2019
$459k
NCI NIH HHS U01 CA260469NIAID NIH HHS R01 AI130066NIAID NIH HHS R01 AI148049NIAID NIH HHS R21 AI139784NIBIB NIH HHS U54 EB007958NIEHS NIH HHS R01 ES026973NIH HHS U24 OD023382
6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has emphasized the importance and challenges of correctly interpreting antibody test results. Identification of positive and negative samples requires a classification strategy with low error rates, which is hard to achieve when the corresponding measurement values overlap. Additional uncertainty arises when classification schemes fail to account for complicated structure in data. We address these problems through a mathematical framework that combines high dimensional data modeling and optimal decision theory. Specifically, we show that appropriately increasing the dimension of data better separates positive and negative populations and reveals nuanced structure that can be described in terms of mathematical models. We combine these models with optimal decision theory to yield a classification scheme that better separates positive and negative samples relative to traditional methods such as confidence intervals (CIs) and receiver operating characteristics. We validate the usefulness of this approach in the context of a multiplex salivary SARS-CoV-2 immunoglobulin G assay dataset. This example illustrates how our analysis: (i) improves the assay accuracy (e.g. lowers classification errors by up to 42 % compared to CI methods); (ii) reduces the number of indeterminate samples when an inconclusive class is permissible (e.g. by 40 % compared to the original analysis of the example multiplex dataset); and (iii) decreases the number of antigens needed to classify samples. Our work showcases the power of mathematical modeling in diagnostic classification and highlights a method that can be adopted broadly in public health and clinical settings.

Identifiers

PMID35795812
PMCPMC9258291
OpenAlexW4284879014

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.